{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:48Z","timestamp":1792783128347,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Farma SpA","id":[{"id":"https:\/\/ror.org\/03fjwdh27","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin condition primarily affecting areas rich in apocrine sweat glands, presenting with comedones, papules, nodules, and abscesses, as well as tunnels and hypertrophic scarring. Despite its prevalence and impact on quality of life, the pathogenesis of HS remains incompletely understood. Notably, its diagnosis often suffers from delays and misidentification, therefore an improved education for healthcare providers is mandatory. Moreover, HS is frequently associated with systemic comorbidities and a multidisciplinary approach is suggested for its management. Recognizing these challenges, a group of Italian HS experts and patients convened to develop consensus guidelines via the Nominal Group Technique. Through iterative meetings and remote collaboration, they identified key areas for improvement and formulated consensus statements to guide healthcare providers in delivering optimal care. This collaborative effort highlights the importance of standardized approaches and interdisciplinary collaboration in managing HS effectively.<\/jats:p>","DOI":"10.1007\/s00403-024-03316-2","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T10:02:10Z","timestamp":1724493730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improving hidradenitis suppurativa management: consensus statements from physicians and patients\u2019 perspectives"],"prefix":"10.1007","volume":"316","author":[{"given":"Angelo Valerio","family":"Marzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Magnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"De Magnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Pintori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Simonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bastioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"issue":"12","key":"3316_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC et al (2020) What causes hidradenitis suppurativa?\u201315\u00a0years after. Exp Dermatol 29(12):1154\u20131170","journal-title":"Exp Dermatol"},{"issue":"24","key":"3316_CR2","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.3390\/jcm12247754","volume":"12","author":"F Antonelli","year":"2023","unstructured":"Antonelli F et al (2023) Clinical features and response to treatment in elderly subjects affected by hidradenitis suppurativa: a cohort study. J Clin Med 12(24):7754","journal-title":"J Clin Med"},{"issue":"2","key":"3316_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","volume":"141","author":"JW Frew","year":"2021","unstructured":"Frew JW et al (2021) A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol 141(2):316\u2013324","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3316_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1159\/000521263","volume":"238","author":"AV Marzano","year":"2022","unstructured":"Marzano AV et al (2022) Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation. Dermatology 238(5):860\u2013869","journal-title":"Dermatology"},{"issue":"8","key":"3316_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/biomedicines10082039","volume":"10","author":"C Moltrasio","year":"2022","unstructured":"Moltrasio C et al (2022) Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines 10(8):2039","journal-title":"Biomedicines"},{"issue":"20","key":"3316_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","volume":"318","author":"DML Saunte","year":"2017","unstructured":"Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019\u20132032","journal-title":"JAMA"},{"issue":"2","key":"3316_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijwd.2020.02.005","volume":"6","author":"E Collier","year":"2020","unstructured":"Collier E et al (2020) Special considerations for women with hidradenitis suppurativa. Int J Womens Dermatol 6(2):85\u201388","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"3316_CR8","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1177\/12034754221116115","volume":"26","author":"LA Johnston","year":"2022","unstructured":"Johnston LA et al (2022) Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg 26(2):2S-24S","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"3316_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173(6):1546\u20131549","journal-title":"Br J Dermatol"},{"issue":"9","key":"3316_CR10","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00403-023-02645-y","volume":"315","author":"SA Chadha","year":"2023","unstructured":"Chadha SA et al (2023) Assessing unmet needs in patients with hidradenitis suppurativa. Arch Dermatol Res 315(9):2555\u20132560","journal-title":"Arch Dermatol Res"},{"key":"3316_CR11","doi-asserted-by":"publisher","first-page":"1145152","DOI":"10.3389\/fmed.2023.1145152","volume":"10","author":"M Daoud","year":"2023","unstructured":"Daoud M et al (2023) Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med (Lausanne) 10:1145152","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"3316_CR12","first-page":"8","volume":"153","author":"L Pescitelli","year":"2018","unstructured":"Pescitelli L, Ricceri F, Prignano F (2018) Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 153(3):8\u201317","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"3316_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R et al (2020) Hidradenitis suppurativa. Nat Rev Dis Primers 6(1):18","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3316_CR14","first-page":"502","volume":"13","author":"N Saito-Sasaki","year":"2023","unstructured":"Saito-Sasaki N, Sawada Y (2023) The development of systemic inflammatory diseases in hidradenitis suppurativa. Diagn (Basel) 13(3):502","journal-title":"Diagn (Basel)"},{"key":"3316_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.12688\/f1000research.11337.1","volume":"6","author":"MK Smith","year":"2017","unstructured":"Smith MK et al (2017) Hidradenitis suppurativa: an update on connecting the tracts. F1000Res 6:1272","journal-title":"F1000Res"},{"key":"3316_CR16","doi-asserted-by":"crossref","unstructured":"Alter M (2024) Hidradenitis suppurativa. Dermatologie (Heidelb)","DOI":"10.1007\/s00105-024-05321-y"},{"issue":"1","key":"3316_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/bjd.13864","volume":"174","author":"V Bettoli","year":"2016","unstructured":"Bettoli V et al (2016) Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 174(1):195\u2013197","journal-title":"Br J Dermatol"},{"issue":"23","key":"3316_CR18","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.3390\/jcm11237240","volume":"11","author":"L Ocker","year":"2022","unstructured":"Ocker L et al (2022) Current medical and surgical treatment of hidradenitis suppurativa\u2014a comprehensive review. J Clin Med 11(23):7240","journal-title":"J Clin Med"},{"issue":"1","key":"3316_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/fampra\/10.1.76","volume":"10","author":"M Gallagher","year":"1993","unstructured":"Gallagher M et al (1993) The nominal group technique: a research tool for general practice? Fam Pract 10(1):76\u201381","journal-title":"Fam Pract"},{"issue":"3","key":"3316_CR20","first-page":"655","volume":"38","author":"SS McMillan","year":"2016","unstructured":"McMillan SS, King M, Tully MP (2016) How to use the nominal group and delphi techniques. Int J Clin Pharm 38(3):655\u2013662","journal-title":"Int J Clin Pharm"},{"key":"3316_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0030-5073(73)90052-4","volume":"9","author":"DH Gustafson","year":"1973","unstructured":"Gustafson DH, Shukla RK, Delbecq A, Walster GW (1973) A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, delphi groups, and nominal groups. Organ Behav Hum Perform 9:280","journal-title":"Organ Behav Hum Perform"},{"key":"3316_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-0-306-47630-3_7","volume":"30","author":"G Rowe","year":"2001","unstructured":"Rowe G, Wright G (2001) Expert opinions in forecasting: role of the delphi technique. Princ Forecast 30:125","journal-title":"Princ Forecast"},{"issue":"7001","key":"3316_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","volume":"311","author":"J Jones","year":"1995","unstructured":"Jones J, Hunter D (1995) Consensus methods for medical and health services research. BMJ 311(7001):376\u2013380","journal-title":"BMJ"},{"key":"3316_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/09537325.2014.941348","volume":"26","author":"D Gallego","year":"2014","unstructured":"Gallego D, Bueno S (2014) Exploring the application of the delphi method as a forecasting tool in information systems and technologies research. Technol Anal Strateg Manag 26:987","journal-title":"Technol Anal Strateg Manag"},{"key":"3316_CR25","volume-title":"The influencing process in group decision making. Group processes","author":"MF Kaplan","year":"1987","unstructured":"Kaplan MF (1987) The influencing process in group decision making. Group processes. Sage Publications, Inc, Thousand oaks"},{"key":"3316_CR26","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2147\/CCID.S301794","volume":"16","author":"CL Snyder","year":"2023","unstructured":"Snyder CL, Chen SX, Porter ML (2023) Obstacles to Early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol 16:1833\u20131841","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"3316_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1684\/ejd.2018.3254","volume":"28","author":"A Chiricozzi","year":"2018","unstructured":"Chiricozzi A et al (2018) The hidradenitis suppurativa (HS) \u201cmultidisciplinary unit\u201d: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol 28(2):274\u2013275","journal-title":"Eur J Dermatol"},{"issue":"6","key":"3316_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/jdv.15850","volume":"33","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Micali G, Veraldi S (2019) The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. J Eur Acad Dermatol Venereol 33(6):15\u201320","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3316_CR29","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","volume":"73","author":"HH van der Zee","year":"2015","unstructured":"van der Zee HH, Jemec GB (2015) New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol 73(5):S23\u2013S26","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3316_CR30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E et al (2021) Hidradenitis suppurativa: where we are and where we are going. Cells 10(8):1013","journal-title":"Cells"},{"issue":"7","key":"3316_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.bpobgyn.2014.07.012","volume":"28","author":"LJ Margesson","year":"2014","unstructured":"Margesson LJ, Danby FW (2014) Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 28(7):1013\u20131027","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"3316_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC et al (2017) Development and validation of the International hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 177(5):1401\u20131409","journal-title":"Br J Dermatol"},{"issue":"2","key":"3316_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jdv.18632","volume":"37","author":"T Tzellos","year":"2023","unstructured":"Tzellos T et al (2023) Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 37(2):395\u2013401","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3316_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","volume":"6","author":"A Timila Touhouche","year":"2020","unstructured":"Timila Touhouche A et al (2020) Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Womens Dermatol 6(3):164\u2013168","journal-title":"Int J Womens Dermatol"},{"key":"3316_CR35","doi-asserted-by":"publisher","first-page":"adv00859","DOI":"10.2340\/actadv.v102.2485","volume":"103","author":"M Otten","year":"2023","unstructured":"Otten M et al (2023) Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research. Acta Derm Venereol 103:adv00859","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3316_CR36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2340\/00015555-0866","volume":"90","author":"L Matusiak","year":"2010","unstructured":"Matusiak L, Bieniek A, Szepietowski JC (2010) Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90(3):264\u2013268","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"3316_CR37","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.3390\/jcm12082755","volume":"12","author":"JE Rymaszewska","year":"2023","unstructured":"Rymaszewska JE et al (2023) Satisfaction with life and coping strategies among patients with hidradenitis suppurativa: a cross-sectional study. J Clin Med 12(8):2775","journal-title":"J Clin Med"},{"issue":"11","key":"3316_CR38","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/jdv.13687","volume":"30","author":"V Bettoli","year":"2016","unstructured":"Bettoli V et al (2016) The hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol 30(11):1965\u20131970","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"3316_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.14826","volume":"47","author":"N Kashetsky","year":"2022","unstructured":"Kashetsky N et al (2022) Patient experiences with hidradenitis suppurativa: the hidradenitis patient experience survey. Clin Exp Dermatol 47(1):72\u201379","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"3316_CR40","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/iwj.13945","volume":"20","author":"B Tang","year":"2023","unstructured":"Tang B et al (2023) Complications of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. Int Wound J 20(4):1253\u20131261","journal-title":"Int Wound J"},{"issue":"7","key":"3316_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1524-4725.2000.00043.x","volume":"26","author":"R Rompel","year":"2000","unstructured":"Rompel R, Petres J (2000) Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 26(7):638\u2013643","journal-title":"Dermatol Surg"},{"issue":"3","key":"3316_CR42","first-page":"20","volume":"153","author":"F Lacarrubba","year":"2018","unstructured":"Lacarrubba F et al (2018) Role of the imaging techniques in the diagnosis and staging of hidradenitis suppurativa. G Ital Dermatol Venereol 153(3):20\u201325","journal-title":"G Ital Dermatol Venereol"},{"issue":"8","key":"3316_CR43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3348\/kjr.2022.0215","volume":"23","author":"S Srisajjakul","year":"2022","unstructured":"Srisajjakul S, Prapaisilp P, Bangchokdee S (2022) Magnetic resonance imaging of hidradenitis suppurativa: a focus on the anoperineal location. Korean J Radiol 23(8):785\u2013793","journal-title":"Korean J Radiol"},{"issue":"1","key":"3316_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.det.2015.08.003","volume":"34","author":"X Wortsman","year":"2016","unstructured":"Wortsman X (2016) Imaging of hidradenitis suppurativa. Dermatol Clin 34(1):59\u201368","journal-title":"Dermatol Clin"},{"issue":"2","key":"3316_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5114\/ada.2021.104274","volume":"38","author":"E Mazeika","year":"2021","unstructured":"Mazeika E, Jariene V, Valiukeviciene S (2021) Medical infrared thermography as hidradenitis suppurativa diagnostic tool: literature review. Postepy Dermatol Alergol 38(2):32\u201335","journal-title":"Postepy Dermatol Alergol"},{"issue":"1\u20133","key":"3316_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2011.08.047","volume":"672","author":"M Nazary","year":"2011","unstructured":"Nazary M et al (2011) Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 672(1\u20133):1\u20138","journal-title":"Eur J Pharmacol"},{"key":"3316_CR47","doi-asserted-by":"publisher","first-page":"918858","DOI":"10.3389\/fgene.2022.918858","volume":"13","author":"G Vellaichamy","year":"2022","unstructured":"Vellaichamy G et al (2022) Recent advances in hidradenitis suppurativa: role of race, genetics, and immunology. Front Genet 13:918858","journal-title":"Front Genet"},{"issue":"5","key":"3316_CR48","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.3390\/cimb45050280","volume":"45","author":"MJ Diaz","year":"2023","unstructured":"Diaz MJ et al (2023) Hidradenitis suppurativa: molecular etiology, pathophysiology, and management\u2014a systematic review. Curr Issues Mol Biol 45(5):4400\u20134415","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"3316_CR49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol 29(4):619\u2013644","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3316_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamadermatol.2022.5390","volume":"159","author":"FR Blum","year":"2023","unstructured":"Blum FR, DeBarmore BM, Sayed CJ (2023) Hidradenitis suppurativa in older adults. JAMA Dermatol 159(2):216\u2013219","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3316_CR51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamadermatol.2020.5435","volume":"157","author":"C Liy-Wong","year":"2021","unstructured":"Liy-Wong C et al (2021) Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients. JAMA Dermatol 157(4):385\u2013391","journal-title":"JAMA Dermatol"},{"issue":"11","key":"3316_CR52","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/biomedicines10112973","volume":"10","author":"E Rosi","year":"2022","unstructured":"Rosi E et al (2022) Hidradenitis suppurativa: the influence of gender, the importance of trigger factors and the implications for patient habits. Biomedicines 10(11):2973","journal-title":"Biomedicines"},{"issue":"6","key":"3316_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/cjp.cjp_67_21","volume":"64","author":"CB Chu","year":"2021","unstructured":"Chu CB, Yang CC, Tsai SJ (2021) Hidradenitis suppurativa: disease pathophysiology and sex hormones. Chin J Physiol 64(6):257\u2013265","journal-title":"Chin J Physiol"},{"issue":"5","key":"3316_CR54","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ijwd.2021.10.012","volume":"7","author":"EK Kozera","year":"2021","unstructured":"Kozera EK et al (2021) Clinical considerations in the management of hidradenitis suppurativa in women. Int J Womens Dermatol 7(5):664\u2013671","journal-title":"Int J Womens Dermatol"},{"issue":"6","key":"3316_CR55","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamadermatol.2020.0777","volume":"156","author":"AB Lyons","year":"2020","unstructured":"Lyons AB et al (2020) Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum. JAMA Dermatol 156(6):681\u2013685","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3316_CR56","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10880-019-09640-4","volume":"27","author":"S Tugnoli","year":"2020","unstructured":"Tugnoli S et al (2020) Anger, emotional fragility, self-esteem, and psychiatric comorbidity in patients with hidradenitis suppurativa\/acne inversa. J Clin Psychol Med Settings 27(3):527\u2013540","journal-title":"J Clin Psychol Med Settings"},{"issue":"4","key":"3316_CR57","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamadermatol.2020.5857","volume":"157","author":"MJ Jedrzejczak","year":"2021","unstructured":"Jedrzejczak MJ et al (2021) Expert knowledge, attitudes, and practices in management of hidradenitis suppurativa pain. JAMA Dermatol 157(4):464\u2013466","journal-title":"JAMA Dermatol"},{"issue":"8","key":"3316_CR58","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/jdv.16255","volume":"34","author":"K Wlodarek","year":"2020","unstructured":"Wlodarek K et al (2020) Psychosocial burden of hidradenitis suppurativa patients\u2019 partners. J Eur Acad Dermatol Venereol 34(8):1822\u20131827","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3316_CR59","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.12688\/f1000research.26083.1","volume":"9","author":"S Narla","year":"2020","unstructured":"Narla S, Lyons AB, Hamzavi IH (2020) The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res 9:1049","journal-title":"F1000Res"},{"issue":"7","key":"3316_CR60","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/jdv.17306","volume":"35","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, Chernyshov PV (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420\u20131421","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3316_CR61","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS et al (2020) The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 183(2):340\u2013348","journal-title":"Br J Dermatol"},{"issue":"6","key":"3316_CR62","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bjd.19798","volume":"184","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203\u20131204","journal-title":"Br J Dermatol"},{"issue":"5","key":"3316_CR63","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA et al (2024) Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol 20(5):525\u2013545","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"3316_CR64","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422\u2013434","journal-title":"N Engl J Med"},{"issue":"10378","key":"3316_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747\u2013761","journal-title":"Lancet"},{"key":"3316_CR66","unstructured":"Bimzelx (bimekizumab) EPAR\u2013Medicine overview, Reference Number: EMA\/250454\/2023 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx"},{"issue":"2","key":"3316_CR67","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A et al (2020) Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) Project. J Am Acad Dermatol 82(2):366\u2013376","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3316_CR68","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part i: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 81(1):76\u201390","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3316_CR69","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.18660","volume":"182","author":"JS Kirby","year":"2020","unstructured":"Kirby JS et al (2020) A narrative review of the definition of \u2018flare\u2019 in hidradenitis suppurativa. Br J Dermatol 182(1):24\u201328","journal-title":"Br J Dermatol"},{"issue":"5","key":"3316_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/bjd.21647","volume":"187","author":"TM LeWitt","year":"2022","unstructured":"LeWitt TM et al (2022) International consensus definition of disease flare in hidradenitis suppurativa. Br J Dermatol 187(5):785\u2013787","journal-title":"Br J Dermatol"},{"issue":"8","key":"3316_CR71","first-page":"e43695","volume":"15","author":"U Rathod","year":"2023","unstructured":"Rathod U et al (2023) Hidradenitis suppurativa: a literature review comparing current therapeutic modalities. Cureus 15(8):e43695","journal-title":"Cureus"},{"issue":"11","key":"3316_CR72","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG et al (2021) Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg 156(11):1001\u20131009","journal-title":"JAMA Surg"},{"issue":"4","key":"3316_CR73","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.13090","volume":"171","author":"CB Kromann","year":"2014","unstructured":"Kromann CB et al (2014) Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 171(4):819\u2013824","journal-title":"Br J Dermatol"},{"issue":"4","key":"3316_CR74","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","volume":"161","author":"K Sartorius","year":"2009","unstructured":"Sartorius K et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161(4):831\u2013839","journal-title":"Br J Dermatol"},{"issue":"4","key":"3316_CR75","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaad.2019.10.044","volume":"82","author":"P Acharya","year":"2020","unstructured":"Acharya P, Mathur M (2020) Hidradenitis suppurativa and smoking: a systematic review and meta-analysis. J Am Acad Dermatol 82(4):1006\u20131011","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3316_CR76","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.1111\/jdv.16494","volume":"34","author":"F Deilhes","year":"2020","unstructured":"Deilhes F et al (2020) Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. J Eur Acad Dermatol Venereol 34(12):e790\u2013e791","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03316-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T12:09:24Z","timestamp":1729685364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03316-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":76,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3316"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03316-2","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.V. Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi, and UCB. F. Prignano has received consulting fees from AbbVie, Amgen, Biogen, Eli-Lilly, Janssen-Cilag, Leo-Pharma, Sanofi, Boehringer-Ingelheim and Novartis and has received research grants from Janssen-Cilag, Novartis, and SIDeMAST.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"577"}}